Pfizer taps oncology chief to map drug-research path amid pressure from activist Starboard
The drug company had been searching for a new chief scientific officer since July with Mikael Dolsten leaving after 15 years at the company.
Pfizer Taps Cancer Chief to Lead Research, Find Hit Drugs
Pfizer Inc. named oncology research head Chris Boshoff as the drug company’s chief scientific officer while it works to fend off activist criticism that its pipeline is underwhelming.
Pfizer Shakes Up C-Suite, Elevating Cancer Chief Boshoff to CSO
Chris Boshoff will take over as Pfizer’s next chief scientific officer as of January 1, replacing Mikael Dolsten who led the pharma through the COVID-19 pandemic. The move comes weeks after Pfizer faced pressure from activist investor Starboard Value.
Pfizer, under pressure to change, names oncology head as new R&D chief
Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.
Pfizer Names New R&D Chief
Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief scientific officer starting Jan. 1.
Pfizer confirms Chris Boshoff as chief scientific officer
Pfizer (PFE) announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD,
Pfizer names oncology head Chris Boshoff as R&D chief
Pfizer said on Wednesday it has named company veteran and oncology head Chris Boshoff as its chief of research and development. The appointment comes at a time when Pfizer is facing criticism from activist investor Starboard for overspending on big acquisitions and failing to produce profitable new drugs from those deals or its internal research and development.
Pfizer Names Oncology Head Boshoff as Chief Science Officer
Pfizer Inc. named oncology research head Chris Boshoff as the drug company’s chief scientific officer, replacing Mikael Dolsten, whose planned departure was announced earlier this year.
Pfizer Names Chris Boshoff Chief Scientific Officer And President, R&D, Effective Jan.1
Drug major Pfizer Inc. (PFE) announced Wednesday the appointment of Chris Boshoff as Chief Scientific Officer and President, Research
Pfizer names insider Chris Boshoff as R&D chief
Pfizer said on Wednesday it has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing for more than a year, as its chief of research and development. The appointment comes at a time when Pfizer is facing pressure from activist investor Starboard,
Pfizer Announces New Chief Scientific Officer and President, Research & Development
Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President,
STAT4d
Investors tell Silence Therapeutics to shush
Silence Therapeutics presented what seemed like positive data on zerlasiran, its experimental drug for reducing ...
MM&M4d
Pfizer promoted oncology chief Chris Boshoff to serve as CSO, R&D president
As for his soon-to-be former role, Boshoff will be succeeded by Dr. Roger Dansey, who will serve as the interim chief ...
ENDPOINTS NEWS4d
Pfiz­er taps on­col­o­gy head Boshoff as Dol­sten's chief sci­en­tif­ic of­fi­cer suc­ces­sor
Chris Boshoff will become Pfizer's chief scientific officer and R&D president on January 1, replacing Mikael Dolsten. Roger ...
STAT4d
Doubling down on its strategy, Pfizer names its head of oncology as new research chief
Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.
Amgen Names Howard Chang as Chief Scientific Officer
Amgen on Wednesday said Howard Chang will join the company as senior vice president of research, effective Dec. 16. The company said Chang, who will also serve as chief scientific officer, will ...